March 2, 2021
The FDA is alerting the public that preliminary results from a safety clinical trial show an increased risk of serious heart-related problems and cancer with Xeljanz, Xeljanz XR (tofacitinib) compared with tumor necrosis factor inhibitors. The safety trial also investigated other potential risks, including blood clots in the lungs and death, but those results are not yet available.
This website uses cookies to improve your experience. By using this website you agree to our Privacy Policy.
Read more